Myostatin inhibition therapy has held much promise for the treatment of muscle wasting
disorders. This is particularly true for the fatal myopathy, Duchenne Muscular Dystrophy …

Background The treatments currently approved for Duchenne muscular dystrophy (DMD), a
progressive skeletal muscle wasting disease, address the needs of only a small proportion …

Duchenne muscular dystrophy (DMD) is a fatal, genetic disorder whose relentless
progression underscores the urgency for developing a cure. Although Duchenne initiated …

Mutations in myostatin (GDF8) cause marked increases in muscle mass, suggesting that this
transforming growth factor‐β (TGF‐β) superfamily member negatively regulates muscle …

The elusive promise of myostatin inhibition for muscular dys... : Current Opinion in Neurology
The elusive promise of myostatin inhibition for muscular dystrophy : Current Opinion in …

Duchenne muscular dystrophy (DMD) is a devastating genetic muscle disease resulting in
progressive muscle degeneration and wasting. Glucocorticoids, specifically prednisone …

In the past 20 years, myostatin, a negative regulator of muscle mass, has attracted attention
as a potential therapeutic target in muscular dystrophies and other conditions. Preclinical …

Since the discovery of the myostatin/ActRIIB signaling pathway 15 years ago, numerous
strategies were developed to block its inhibitory function during skeletal muscle growth …

Background Myostatin inhibition is a promising therapeutic strategy to maintain muscle mass
in a variety of disorders, including the muscular dystrophies, cachexia, and sarcopenia …

Muscular dystrophies are characterized by weakness and wasting of skeletal muscle
tissues. Several drugs targeting the myostatin pathway have been used in clinical trials to …